Marketing: Page 2


  • Image attribution tooltip
    Permission granted by Amylyx Pharmaceuticals
    Image attribution tooltip
    ALS drug development

    Amylyx’s ALS drug gets pushback from European regulators

    An EMA committee expressed concern with the main study meant to show Amylyx’s drug is safe and effective. The company now plans to ask for a re-examination of its approval application.

    By June 23, 2023
  • former Illumina CEO Francis deSOuza
    Image attribution tooltip
    Kevin Dietsch via Getty Images
    Image attribution tooltip

    As Illumina’s deSouza departs, will Grail go next?

    The CEO’s resignation signals a change of direction, as anti-trust regulators order Illumina to divest the liquid biopsy unit.

    By Susan Kelly • June 12, 2023
  • Explore the Trendline
    Image attribution tooltip
    Brian Tucker / BioPharma Dive
    Image attribution tooltip
    Trendline

    Pharma, new drugs and market strategy

    New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.

    By BioPharma Dive staff
  • The logo of German pharmaceuticals and chemicals giant Bayer stands over Bayer corporate offices on September 14, 2016 in Berlin, Germany.
    Image attribution tooltip
    Sean Gallup via Getty Images
    Image attribution tooltip

    Bayer launches precision health unit in latest digital health venture

    The pharma company said it will work with startups and other digital health companies as it builds out the consumer-focused business unit.

    By Emily Olsen • June 1, 2023
  • Two mature smiling doctors having discussion about patient diagnosis, holding digital tablet.
    Image attribution tooltip

    Ground Picture/Shutterstock.com

    Image attribution tooltip
    Sponsored by Veeva

    2023 Veeva trends in HCP omnichannel engagement report

    Boost campaign effectiveness by 23% by synchronizing sales and marketing.

    May 30, 2023
  • Rep. Comer sits in front of a poster outlining the cost differences between a drug dispensed at Cost Plus Drugs versus CVS.
    Image attribution tooltip
    Rebecca Pifer/BioPharma Dive
    Image attribution tooltip

    House lawmakers, PBM lobby spar over committee hearing

    At the latest congressional inquiry into pharmacy benefit managers, lawmakers argued the middlemen profit at the expense of patients and taxpayers.

    By Rebecca Pifer • May 25, 2023
  • The logo of Amylyx Pharmaceuticals is seen through an office window.
    Image attribution tooltip
    Permission granted by Amylyx Pharmaceuticals
    Image attribution tooltip

    Amylyx’s ALS drug again surpasses Wall Street expectations

    Revenue from the biotech’s ALS therapy Relyvrio totaled $71.4 million in the first quarter, well above analyst estimates and helping the company turn a profit only months into the drug’s launch.

    By May 11, 2023
  • Close up of a testing card that says 'control' and 'sample', with a thin red line next to each.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip

    Here’s what will change when the COVID public health emergency ends

    Vaccines, which have been crucial to curbing the virus’ spread, will remain free for the vast majority of people in the U.S., but over-the-counter tests will no longer be covered for most.

    By Shannon Muchmore • May 10, 2023
  • a photo illustration showing packages of Mifepristone tablets
    Image attribution tooltip
    Anna Moneymaker/Getty Images via Getty Images
    Image attribution tooltip

    Abortion providers in 3 states sue over mifepristone restrictions

    The lawsuit seeks to remove safety restrictions on mifepristone or, alternatively, prevent further altering of access to the drug.

    By Sydney Halleman • May 9, 2023
  • Image attribution tooltip
    Jeenah Moon via Getty Images
    Image attribution tooltip

    Pfizer turns focus to new drugs as COVID vaccine revenue falls

    The drugmaker beat Wall Street’s first quarter forecasts despite a sales drop that puts pressure on it to succeed with upcoming market launches.

    By May 2, 2023
  • Lilly plans dash to market for weight loss drug after trial win

    The drugmaker will use a priority review voucher in a bid to secure FDA approval of Mounjaro in obesity by late this year or early next.

    By April 27, 2023
  • Roche Pharmaceutical Group's office building in Shanghai, China
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Roche’s new eye drug pressures Eylea with strong launch

    One year after its market debut, the company’s AMD drug Vabysmo is on track for blockbuster sales as Regeneron’s rival treatment faces new threats.

    By April 26, 2023
  • Lilly sells emergency diabetes drug for $500M

    The divestment of Baqsimi to Amphastar could net Lilly more than $1 billion if sales goals are met.

    By April 24, 2023
  • People gather outside the U.S. Supreme Court in Washington, D.C. on Friday, April 21.
    Image attribution tooltip
    Michaela Wong/BioPharma Dive
    Image attribution tooltip

    Supreme Court maintains access to abortion pill, blocking restrictions on its use

    The stay suspends a Texas judge’s order that invalidated the FDA’s approval of mifepristone, keeping it available while a circuit court hears the case.

    By Updated April 22, 2023
  • A side-view of the Supreme Court building with a view of a raised flag pole
    Image attribution tooltip
    Anna Moneymaker/Getty Images via Getty Images
    Image attribution tooltip

    Supreme Court delays decision in battle over abortion pill

    An administrative stay of a Texas district court ruling will remain in place through Friday, pushing out a Supreme Court decision in the closely watched case over the drug mifepristone.

    By April 19, 2023
  • Close-up of a sign with office building and trees in background
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    FDA again knocks back Alvotech’s Humira biosimilar

    The agency rejected the partners’ copycat version of AbbVie’s blockbuster drug for a second time, citing problems spotted during the inspection of a manufacturing facility.

    By April 14, 2023
  • Novo boosts sales outlook on strong demand for obesity drug

    The Danish drugmaker nearly doubled the 2023 forecasts for Wegovy and Ozempic in the latest indicator of the sales potential of an emerging and competitive class of weight loss drugs. 

    By Kristin Jensen • April 13, 2023
  • Boxes of mifepristone, the first pill given in a medical abortion
    Image attribution tooltip

    Evelyn Hockstein / Reuters

    Image attribution tooltip

    Federal judge invalidates FDA approval of abortion pill

    The decision imperils access to the drug more than two decades after its U.S. approval, and could carry consequences for the FDA’s authority over prescription medicines.

    By April 8, 2023
  • A man speaks in front of a microphone at a hearing.
    Image attribution tooltip
    Kevin Dietsch via Getty Images
    Image attribution tooltip

    FDA withdraws preterm birth drug’s approval, denying maker’s request for delay

    Commissioner Robert Califf and Chief Scientist Namandjé Bumpus determined there was “no justification” for keeping Covis Pharma’s controversial treatment Makena on the market.

    By April 6, 2023
  • The Federal Trade Commission headquarters is pictured in Washington, D.C. The agency's proposed noncompete ban may face legal challenges on several grounds.
    Image attribution tooltip
    RiverNorthPhotography via Getty Images
    Image attribution tooltip

    FTC wades into dispute between Supernus, generic competitor

    The agency, which is taking a closer look at the pharma industry, submitted a brief to federal court in a case it says could have “significant implications” for Parkinson’s patients.

    By Kristin Jensen • March 22, 2023
  • Pear Therapeutics prescription digital therapeutic Somryst for chronic insomnia
    Image attribution tooltip
    Permission granted by Pear Therapeutics
    Image attribution tooltip

    Pear, tight on cash, considers strategic alternatives

    The digital therapeutics firm is considering a sale, merger or other deal following struggles to market its app-based treatments.

    By Elise Reuter • March 17, 2023
  • Brain MRI scan
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    VA to cover Leqembi for veterans with early Alzheimer’s

    The agency’s decision on Eisai and Biogen’s new drug contrasts with a stringent Medicare policy that limits coverage to patients in clinical trials.

    By March 14, 2023
  • A photograph of a box of Amylyx Pharmaceuticals' ALS medicine Relyvrio
    Image attribution tooltip
    Permission granted by Amylyx Pharmaceuticals
    Image attribution tooltip
    ALS drug development

    Amylyx’s ALS drug sales impress Wall Street

    In its first full quarter on the market, Amylyx’s Relyvrio generated nearly $22 million in revenue, or about five times what some analysts forecast last month.

    By March 13, 2023
  • Exterior of FDA headquarters
    Image attribution tooltip
    Courtesy of U.S. Food and Drug Administration
    Image attribution tooltip

    FDA clears first at-home flu and COVID test, days after its developer files for bankruptcy

    The test’s maker, Lucira, said the agency’s “protracted” authorization process caused it to miss out on test sales in the latest flu season.

    By Nick Paul Taylor • Feb. 27, 2023
  • A vial of Eisai and Biogen's Alzheimer's disease drug Leqembi
    Image attribution tooltip
    Courtesy of Eisai
    Image attribution tooltip

    Medicare maintains limits on Eisai’s new Alzheimer’s drug

    Eisai and Biogen have data showing Leqembi slows cognitive decline, but CMS won’t budge until FDA converts its approval from accelerated to full.

    By Feb. 23, 2023
  • Amjevita carton
    Image attribution tooltip
    Permission granted by Amgen
    Image attribution tooltip

    Doctors largely comfortable with biosimilar drugs, but question economics: report

    Weeks after the first Humira copycat launched in the U.S., a survey by Cardinal Health suggests insurer mandates will drive biosimilar adoption.

    By Feb. 22, 2023